According to Benzinga Pro, Stryker's peer group average for short interest as a percentage of float is 5.30%, which means the ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

Stryker received FDA 510(k) clearance for its Incompass® Total Ankle System, intended for patients with severe ...

This was the stock's third consecutive day of gains.

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to ...

America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...

Williams County Public Library will hold a retirement reception in honor of Stryker Library Assistant Linda Woodall.

“Aptose is incredibly grateful for Hanmi’s continued support tuspetinib,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. “Our data to date in the TUS+VEN+AZA ...